TY - JOUR
T1 - Decentralization of snakebite antivenom treatment to indigenous community health centers in the Brazilian Amazon
T2 - From demand to the first treatment (the SAVING Program)
AU - Seabra de Farias, Altair
AU - Serrão-Pinto, Thiago
AU - Cardoso, Deugles
AU - Augusto Guimarães Figueira, Elder
AU - Almeida-Val, Fernando
AU - Amorim Ramos, Tatyana
AU - Dourado, Flávio Santos
AU - de Lima-Junior, Francisco Edilson Ferreira
AU - Montebello, Lucia
AU - Filho, Manoel Rodrigues Gomes
AU - Ipuchima, Leonardo da Silva
AU - de Souza, Nilzoney Ferreira
AU - Arévalo, Macio da Costa
AU - Lacerda, Marcus
AU - Machado, Vinícius Azevedo
AU - Murta, Felipe
AU - Gerardo, Charles
AU - Vissoci, João
AU - Wen, Fan Hui
AU - Sachett, Jacqueline
AU - Monteiro, Wuelton
N1 - Publisher Copyright:
© 2025 Seabra de Farias et al.
PY - 2025/4
Y1 - 2025/4
N2 - Brazilian antivenoms have excellent efficacy in recovering venom-induced coagu-lopathy, in addition to having a good safety profile with only 10% of patients experi-encing a mild reaction such as urticaria or pruritus. More than 3.5 hundred thousand snakebite antivenom vials are produced per year, and all the batches are acquired by the Ministry of Health and distributed free of charge to 2,200 hospitals across the national territory. However, these health facilities are unevenly distributed across the territory, so that the distance a patient needs to travel to receive care is much greater in the Amazon region in comparison to the extra-Amazonia region, leading to a huge access barrier in this region. The lack of access to healthcare facilities for snakebite patients may be greater than 30% in some regions of the Amazonia. The decentralization of SBE treatment with antivenoms to the scope of indigenous community health centers requires the discussion of proper organizational designs and arrangements of practices based on the user needs, singularities of the territory, and the clinical reality of the indigenous populations. In this report, we describe a successful experience of decentralization of antivenom treatment for an indigenous health unit in the Brazilian Amazon, which provides a platform to improve the lives of SBE patients at risk of this life-threatening condition. In this work, we report the experience in the development and implementation of a program to decentralize antivenom treatment for indigenous communities, which represents a significant change in the national policy for snakebite control, with a potential impact on reducing morbidity and mortality from this health problem. In the next steps, SAVING Program will be evaluated through mixed-method studies in regards team and community’s experience within the program, aiming to identify barriers, perceptions about the implementation pro-cess, and facilitators for the maintenance/sustainability.
AB - Brazilian antivenoms have excellent efficacy in recovering venom-induced coagu-lopathy, in addition to having a good safety profile with only 10% of patients experi-encing a mild reaction such as urticaria or pruritus. More than 3.5 hundred thousand snakebite antivenom vials are produced per year, and all the batches are acquired by the Ministry of Health and distributed free of charge to 2,200 hospitals across the national territory. However, these health facilities are unevenly distributed across the territory, so that the distance a patient needs to travel to receive care is much greater in the Amazon region in comparison to the extra-Amazonia region, leading to a huge access barrier in this region. The lack of access to healthcare facilities for snakebite patients may be greater than 30% in some regions of the Amazonia. The decentralization of SBE treatment with antivenoms to the scope of indigenous community health centers requires the discussion of proper organizational designs and arrangements of practices based on the user needs, singularities of the territory, and the clinical reality of the indigenous populations. In this report, we describe a successful experience of decentralization of antivenom treatment for an indigenous health unit in the Brazilian Amazon, which provides a platform to improve the lives of SBE patients at risk of this life-threatening condition. In this work, we report the experience in the development and implementation of a program to decentralize antivenom treatment for indigenous communities, which represents a significant change in the national policy for snakebite control, with a potential impact on reducing morbidity and mortality from this health problem. In the next steps, SAVING Program will be evaluated through mixed-method studies in regards team and community’s experience within the program, aiming to identify barriers, perceptions about the implementation pro-cess, and facilitators for the maintenance/sustainability.
UR - http://www.scopus.com/inward/record.url?scp=105004481503&partnerID=8YFLogxK
U2 - 10.1371/journal.pntd.0013011
DO - 10.1371/journal.pntd.0013011
M3 - Article
C2 - 40305592
AN - SCOPUS:105004481503
SN - 1935-2727
VL - 2025
JO - PLoS Neglected Tropical Diseases
JF - PLoS Neglected Tropical Diseases
M1 - e0013011
ER -